MedTrace Logo

Nalbuphine Versus Dexmedetomidine for Prevention of Emergence Agitation in Pediatrics

NCT05273671 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2022-04-08

No results posted yet for this study

Summary

the investigators hypothesized that Nalbuphine may be alternative pharmacological agent for prevention of emergence agitation in pediatrics who will be scheduled for elective lower abdominal surgical procedures (inguinal hernia repair and hypospadias) during sevoflurane anesthesia

Conditions

  • Agitation

Interventions

DRUG

Nalbuphine

will receive 0.1 mg/kg NAL diluted in 10 ml I.V 10 minutes before the end of surgery

DRUG

Dexmedetomidine

will receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery

DRUG

normal Saline

will receive with a saline solution 10 min before the end of surgery

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • yasser M osman · Alexandria University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2022-06-01
Completion
2022-06-02

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05273671 on ClinicalTrials.gov